Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment

NCT07147101 · clinicaltrials.gov ↗

RECRUITING

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Advanced Hepatocellular Carcinoma (HCC)

Interventions

DRUG: Sintilimab
DRUG: Bevacizumab Biosimilar
DRUG: Camrelizumab
DRUG: Rivoceranib
DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

Fudan University